CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 29.52×, higher than 95% of its Biotechnology peers (median 5.71×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
408.55MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4540xvs all stocks
52-Week Change
103.72%vs all stocks
Market Capitalization
408.55MUSDvs all stocks (USD)
Enterprise Value
190.81MUSDvs all stocks (USD)
Forward P/E
-9.34xvs Biotechnology peers
Price to Book (MRQ)
1.98xvs Biotechnology peers
Enterprise to EBITDA
-3.21xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-32.39%vs Biotechnology peers
Return on Equity (TTM)
-55.66%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-61.93MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-45.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.65MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-59.10MUSDvs all stocks (USD)
Pre-tax Income
-57.39MUSDFY2025 · Dec 31, 2025Net Income
-57.39MUSDFY2025 · Dec 31, 2025EBIT
-59.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-59.42MUSDFY2025 · Dec 31, 2025Research & Development
26.88MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
32.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.45USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.45USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-57.39MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-44.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.50MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-57.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
905.23KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.56MUSDFY2025 · Dec 31, 2025Purchase of Investments
-83.83MUSDFY2025 · Dec 31, 2025Sale of Investments
35.69MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-48.14MUSDFY2025 · Dec 31, 2025Other Financing Charges
-73.02KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
93.56MUSDFY2025 · Dec 31, 2025Shares Outstanding
106.67MSharesUpdated Sep 28, 2026Float Shares
82.64MSharesUpdated Sep 28, 2026Shares Short
14.46MSharesUpdated Sep 28, 2026Short Ratio
12.43daysvs all stocks
Short % of Shares Outstanding
14.40%vs all stocks
% Held by Insiders
3.23%vs all stocks
% Held by Institutions
94.65%vs all stocks
Total Cash (MRQ)
217.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.04USDUpdated Sep 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
29.52xvs Biotechnology peers
Book Value per Share (MRQ)
1.94USDUpdated Sep 28, 2026Total Assets
94.00MUSDvs all stocks (USD)
Total Current Assets
93.98MUSDFY2025 · Dec 31, 2025Total Liabilities
7.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
19.50KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.50MUSDFY2025 · Dec 31, 2025Other Short-term Investments
89.51MUSDFY2025 · Dec 31, 2025Accounts Payable
1.57MUSDFY2025 · Dec 31, 2025Other Current Liabilities
-17.00USDFY2025 · Dec 31, 2025Common Stock (Book)
73.33KUSDFY2025 · Dec 31, 2025Retained Earnings
-698.27MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
86.51MUSDvs all stocks (USD)
52-Week Low
1.78USDUpdated Sep 28, 202652-Week High
8.00USDUpdated Sep 28, 202652-Week Change
103.72%vs all stocks
Beta
0.4540xvs all stocks
50-Day MA
4.67USDUpdated Sep 28, 2026200-Day MA
5.47USDUpdated Sep 28, 2026Avg 10-Day Volume
1.19MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.13MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.9100USDUpdated Sep 28, 2026Other Income / Expense
319.05KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 29.52×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 29.52Industry median: 5.71Industry P95: 22.21Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule